Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor of Medicine
University of Pennsylvania’s Perelman School of Medicine
Perelman Center for Advanced Medicine
Aparna Parikh, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Hematology and Oncology
Massachusetts General Hospital
This activity will cover the impending use of cfDNA assays in clinical practice to identify various types of cancer earlier.
This activity is intended for primary care physicians, internists, family practice physicians, and related healthcare professionals involved in the care of people who undergo screening for cancer.
After completing the CME activity, learners should be better able to:
- Describe next-generation sequencing assays for cfDNA analysis for multi-cancer early detection
- Discuss emerging data on the clinical validity and utility of cfDNA blood tests in early detection of cancer
- Plan strategies to integrate cfDNA blood tests and early multi-cancer detection into daily practice
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of people who undergo screening for cancer.
Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Charu Aggarwal, MD, MPH reports advisory board/consulting for AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck, and Roche; and research to institution from Macrogenics, AstraZeneca, Merck, and Incyte.
Aparna Parikh, MD, MPH reports advisory board/consulting for Eli Lilly, and Natera; and Checkmate research to institution from Bristol-Myers Squibb, Guardant, Array, Pfizer, Macrogenics, and Takeda.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to participating at email@example.com
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.